您所在的位置: 首页 --> 导师团队 --> 盛锡楠

导师基本信息

  • 姓名:盛锡楠
  • 性别:
  • 民族:汉族
  • 科室:肾癌黑色素瘤内科
  • 职称:主任医师 ,副教授
  • 专业:肿瘤学 、肿瘤内科学
  • E-MAIL: doctor_sheng@126.com

学术论文 | 奖励表彰 | 科研项目 | 招生计划

Li X, Li S, Chi Z, Cui C, Si L, Yan X, Mao L, Lian B, Tang B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Guo J, Sheng X. Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma.,Urol Oncol,2020 Jul 9:S1078-1439(20)30277-5.

Sheng X, Jin J, He Z, Huang Y, Zhou A, Wang J, Ren X, Ye D, Zhang X, Qin S, Zhou F, Wang B, Guo J. Pazopanib Versus Sunitinib in Chinese Patients With Locally Advanced or Metastatic Renal Cell Carcinoma: Pooled Subgroup Analysis From the Randomized, COMPARZ Studies,BMC Cancer,2020 Mar 14;20(1):219

Sheng X, Yan X, Chi Z, Cui C, Si L, Tang B, Li S, Mao L, Lian B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Ding L, Mao L, Guo J. Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.,EBioMedicine,2020 May;55:102755

Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, Bin Lian, Xuan Wang, Xue Bai, Li Zhou, Yan kong, Jie Dai, Kai Wang, Xiongwen Tang, Huaning Zhou, Hai Wu, Hui Feng, Sheng Yao, Keith T. Flaherty, Jun Guo. Axitinib in combination with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with metastatic mucosal melanoma: a non-randomized, open-label, dose-finding, and cohort-expansion phase 1b trial.,Journal of Clinical Oncology,2019 Nov 10;37(32):2987-2999.

Guo X, Zhu H, Liu T, Xu X, Kong Y, Yao S, Sheng X*, Yang Z. Development of 99m Tc-conjugated JS001 Antibody for in Vivo Mapping of PD-1 Distribution in Murine,Bioorg Med Chem Lett,2019 Aug 15;29(16):2178-2181

Yu S, Dai J, Ma M, Xu T, Kong Y, Cui C, Chi Z, Si L, Tang H, Yang L, Sheng X*, Guo J.RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.,Cell Death Dis.,10(4):254.

Sheng X, Bi F, Ren X, Cheng Y, Wang J, Rosbrook B, Jiang M, Guo J.First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data.,Future Oncol,15(1):53-63.

Sheng X, Cao D, Yuan J, Zhou F, Wei Q, Xie X, Cui C, Chi Z, Si L, Li S, Mao L, Lian B, Tang B, Yan X, Wang X, Kong Y, Dai J, Bai X, Zhou L, Guo J.Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study.,Eur J Cancer,100:1-7

Li S, Sheng X#, Si L, Cui C, Kong Y, Mao L, Lian B, Tang B, Yan X, Wang X, Chi Z, Guo J. Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China.,Ann Surg Onol,25(4):885-893.

Kong Y, Sheng X#, Wu X, Yan J, Ma M, Yu J, Si L, Chi Z, Cui C, Dai J, Li Y, Yu H, Xu T, Tang H, Tang B, Mao L, Lian B, Wang X, Yan X, Li S, Guo J. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma indicate the potential for CDK4/6 Inhibitors in Targeted Therapy,Clin Cancer Res,2017epub

Zhang HL, Sheng XN#, Li XS, Wang HK, Chi ZH, He ZS, Ye DW, Guo J.Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.BMC Cancer. 2017 Jan 5;17(1):16. ,BMC Cancer ,2017;17:16

Sheng X, Kong Y, Li Y, Zhang Q, Si L, Cui C, Chi Z, Tang B, Mao L, Lian B, Wang X, Yan X, Li S1, Dai J, Guo J. GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis. Eur J Cancer. 2016 Sep; 65:156-63 ,Eur J Cancer ,

Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget. 2016 May 10; 7(19): 27044-54. ,Oncotarget ,

如何修改住院医师病历 , 指导医师培训 , 第1完成人 , 北京大学肿瘤医院 , 2017.5

以PD-L1为生物标记物的晚期上尿路尿路上皮癌的免疫治疗研究 , 课题负责人 , 2016.6.7~2019.6.7, 北京市科委首都临床特色应用研究/Z161100000516062

研究生招生计划
招生年度 招生专业 学位级别 学位类型 研究方向 选拔方式
2021 肿瘤内科学 硕士 专业学位 临床技能训练与研究 全国统考